- Conditions
- Alcohol Withdrawal Syndrome
- Interventions
- Not listed
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 409 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Stanford, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 1,609
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Autism Spectrum Disorder
- Interventions
- GWP42003-P, Placebo
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Angeles, California + 9 more
- Conditions
- Suicide, Risk Reduction
- Interventions
- Building Stronger Allies, Health Education Training
- Behavioral
- Lead sponsor
- Florida State University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 233 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Fort Campbell North, Kentucky
- Conditions
- Chronic Granulomatous Disease (CGD)
- Interventions
- Busulfan, Tocilizumab, Eltrombopag, Sirolimus, pCCLChimGp91lentiviral vector containing the human gp91 phox (CYBB) gene
- Drug · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 3 Years to 60 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Interventions
- busulfan, cyclophosphamide, cyclosporin-A, etoposide, methotrexate, rasburicase, sirolimus, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, total-body irradiation, fludarabine, allopurinol
- Drug · Procedure · Radiation
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- HIV, Alcohol Use, Medication Adherence
- Interventions
- Immediate PLUS intervention, Wait-list PLUS intervention
- Behavioral
- Lead sponsor
- Hunter College of City University of New York
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 174 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Orthostatic Hypotension, Parkinson's Disease
- Interventions
- Droxidopa, Placebo
- Drug · Other
- Lead sponsor
- Chelsea Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 60
- States / cities
- Alabaster, Alabama • Gilbert, Arizona • Phoenix, Arizona + 53 more
- Conditions
- Alcohol Use Disorder, Alcohol Drinking, Alcohol Use Disorder (AUD)
- Interventions
- ASP8062, Placebo
- Drug
- Lead sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- NIH
- Eligibility
- 21 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Aurora, Colorado • Providence, Rhode Island
- Conditions
- Traumatic Brain Injury (TBI), Hazardous and Harmful Alcohol Use
- Interventions
- Medical Management Counseling, Topiramate, Placebo
- Behavioral · Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Alcohol Use Disorder, Sexually Transmitted Diseases
- Interventions
- Standardized kudzu, Placebo, Sexually transmitted infection testing:, Medical Management (MM) counseling for alcohol use:, Urinalysis for novel alcohol biochemical markers for recent alcohol use:, Dried Blood Spot (DBS) Testing for PEth:, Behavioral survey measurements:, Ecological Momentary Assessment procedure:
- Drug · Other · Diagnostic Test + 1 more
- Lead sponsor
- Glenn-Milo Santos
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Amivantamab IV, Amivantamab SC, Lazertinib, Doxycycline, Minocycline, Clindamycin, Chlorhexidine, Noncomedogenic skin moisturizer, Ruxolitinib, Tacrolimus, Zinc gluconate, Propranolol, Timolol, Clobetasol
- Drug · Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 305 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 28
- States / cities
- Chandler, Arizona • Duarte, California • Fullerton, California + 25 more
- Conditions
- Post-Traumatic Stress Symptoms, Problematic Use of Alcohol or Other Drugs
- Interventions
- Web-based Cognitive Behavioral Treatment
- Behavioral
- Lead sponsor
- National Development and Research Institutes, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 216 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 2
- States / cities
- Buffalo, New York • Syracuse, New York
- Conditions
- Alcohol Use Disorder, Alcohol Use Disorder (AUD)
- Interventions
- STAR
- Device
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 416 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Colorectal Cancer, Colorectal Carcinoma
- Interventions
- Fecal Immunochemical Test (FIT) Kit, Culturally targeted Photo Novella Booklet, Screen for Life Brochure
- Other · Behavioral
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 331 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- DOCK8 Deficiency
- Interventions
- Reduced-intensity hematopoietic stem cell, Fludarabine(Fludara, Berlex Laboratories), Cyclophosphamide(CTX, Cytoxan), Total Body Irradiation (TBI), Busulfan (Busulfex), Donor peripheral blood stem cell mobiliation and collection, Bone Marrow Harvest Procedure
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 4 Years to 120 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2028
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Heart Disease, Mitral Regurgitation, Heart Valve Disease, Mitral Valve Insufficiency
- Interventions
- Beta-blocker therapy (TOPROL-XL® )
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Chronic Granulomatous Disease
- Interventions
- Sirolimus, Cyclophosphamide, Alemtuzumab, Busulfan, Pheripheral blood stem cells, Emapalumab-Izsg, Tociluzumab, Total Body Irradiation
- Drug · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 4 Years to 65 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2032
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Healthy
- Interventions
- Delta-9-THC, N-acetylcysteine, Placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- West Haven, Connecticut
- Conditions
- Alcohol Abstinence
- Interventions
- Guanfacine XR 3mgs/daily, Placebo (for guanfacine)
- Drug
- Lead sponsor
- Stony Brook University
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Stony Brook, New York
- Conditions
- Stress, Physiological, Ethanol Intoxication, Distress, Emotional
- Interventions
- Relevant Trier Social Stressor Test (TSST), Ethanol, Placebo Trier Social Stressor Test (TSST), Placebo Beverage, Irrelevant Trier Social Stressor Test (TSST)
- Behavioral · Drug
- Lead sponsor
- Texas Tech University
- Other
- Eligibility
- 21 Years to 29 Years
- Enrollment
- 165 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Lubbock, Texas
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unusual Cancers of Childhood
- Interventions
- anti-thymocyte globulin, filgrastim, busulfan, carmustine, cyclophosphamide, cyclosporine, cytarabine, etoposide, fludarabine phosphate, melphalan, methotrexate, methylprednisolone, mycophenolate mofetil, tacrolimus, peripheral blood stem cell transplantation, umbilical cord blood transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- Up to 60 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Alcohol Dependence, Alcohol Abuse
- Interventions
- Motivational Interviewing, Spirit-Only Motivational Interviewing, Self-Change
- Behavioral · Other
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Alcohol Use Disorder With Insomnia
- Interventions
- Cognitive Behavioral Therapy for Insomnia, Sleep Hygiene Education
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 2
- States / cities
- Coatesville, Pennsylvania • Philadelphia, Pennsylvania
- Conditions
- Graft-versus-host Disease (GVHD)
- Interventions
- Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX), Mycophenolate mofetil (MMF), mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus), Infliximab, Rituximab, Pentostatin, Imatinib, Ibrutinib
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 38
- States / cities
- Tucson, Arizona • Duarte, California • La Jolla, California + 28 more